Design, synthesis, and antibacterial activity study of pyrroloquinazoline diamine derivatives
Journal of Enzyme Inhibition and Medicinal Chemistry · 31.12.2026 · 41 (1)
DOI: 10.1080/14756366.2026.2690351 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Enzyme Inhibition and Medicinal Chemistry, online erschienen am 24.06.2026. Verfasst von Muchun Cheng und 12 weiteren Autor:innen. Beteiligte Einrichtung: Affiliated Hospital of Jinggangshan University, Jiangxi Province Key Laboratory of Organ Development and Epigenetics, College of Traditional Chinese …. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Drug Design, Quinazolines, Diamines. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Science Foundation of China, Natural Science Foundation of Jiangxi Province, China.
Abstract (Originalsprache)
To combat antimicrobial resistance (AMR), a novel series of pyrrolo[3,2-f]quinazoline-diamine (PQD) derivatives (5a–5z) featuring a flexible benzyl-oxo-benzyl side chain were designed and synthesised via structural optimisation of lead compound IRS-16. All compounds exhibited potent dihydrofolate reductase (DHFR) inhibition. Compound 5a was most notable, showing exceptional enzymatic inhibition (IC50 = 0.92 nM), surpassing both IRS-16 and trimethoprim. 5a demonstrated broad-spectrum antibacterial activity against Gram-positive (e.g., E. faecalis) and Gram-negative strains (e.g., E. coli), as well as clinical isolates of S. aureus, K. pneumoniae, and uropathogenic E. coli (UPEC), with MIC values as low as 0.5 μg/mL. It displayed rapid bactericidal action, low resistance propensity, and inhibited biofilm formation by >90% at 0.5 μg/mL. Additional mechanisms included disruption of bacterial membrane integrity, causing leakage of cellular contents. These results identify 5a as a promising lead for developing novel, broad-spectrum DHFR inhibitors with a low resistance risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Affiliated Hospital of Jinggangshan University, Jiangxi Province Key Laboratory of Organ Development and Epigenetics, College of Traditional Chinese Medicine and Pharmacy, Jinggangshan University, Ji'an, Jiangxi, P.R. C…
- School of Medicine, Tongji University, Shanghai, China.
Förderung
- National Science Foundation of China
- Natural Science Foundation of Jiangxi Province, China
Zitieren
APA
Cheng, M., Tian, Y., Shang, J., He, W., Zheng, Y., Yan, C., Chen, X., Li, J., Jiang, Y., Fu, Q., Deng, X., Xiao, X., & Song, M. (2026). Design, synthesis, and antibacterial activity study of pyrroloquinazoline diamine derivatives. Journal of Enzyme Inhibition and Medicinal Chemistry, 41(1). https://doi.org/10.1080/14756366.2026.2690351
Vancouver
Cheng M, Tian Y, Shang J, He W, Zheng Y, Yan C, et al. Design, synthesis, and antibacterial activity study of pyrroloquinazoline diamine derivatives. Journal of Enzyme Inhibition and Medicinal Chemistry. 2026;41(1). doi:10.1080/14756366.2026.2690351
BibTeX
@article{Cheng2026,
author = {Cheng, Muchun and Tian, YaJing and Shang, JieYa and He, Weiqing and Zheng, Ying and Yan, Can and Chen, Xinyu and Li, Jiawei and Jiang, YuanYing and Fu, Qiang and Deng, Xianqing and Xiao, Xunli and Song, Mingxia},
title = {Design, synthesis, and antibacterial activity study of pyrroloquinazoline diamine derivatives},
journal = {Journal of Enzyme Inhibition and Medicinal Chemistry},
year = {2026},
volume = {41},
number = {1},
doi = {10.1080/14756366.2026.2690351}
}
EUVIMED